A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Trial Profile

A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications MALT lymphoma
  • Focus Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 06 Feb 2017 Results assessing efficacy and safety of ibrutinib published in the Blood.
    • 19 Jan 2017 Results published in a Janssen Biotech media release.
    • 19 Jan 2017 According to a Janssen Biotech media release, based on the data from this study, the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top